Anmelden Kostenlos registrieren

Last updated: 15 June 2020 at 6:34pm EST

Roy Proujansky Net Worth



Roy Proujansky NMTR stock SEC Form 4 insiders trading

Roy has made over 4 trades of the 9 Meters Biopharma stock since 2018, according to the Form 4 filled with the SEC. Most recently Roy bought 1,000 units of NMTR stock worth $1,280 on 24 May 2019.

The largest trade Roy's ever made was buying 1,400 units of 9 Meters Biopharma stock on 30 November 2018 worth over $3,682. On average, Roy trades about 533 units every 19 days since 2018. As of 24 May 2019 Roy still owns at least 2,400 units of 9 Meters Biopharma stock.

You can see the complete history of Roy Proujansky stock trades at the bottom of the page.



What's Roy Proujansky's mailing address?

Roy's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH, NC, 27615.

Insiders trading at 9 Meters Biopharma

Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo und John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.



What does 9 Meters Biopharma do?

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.



What does 9 Meters Biopharma's logo look like?

9 Meters Biopharma, Inc. logo

9 Meters Biopharma executives and stock owners

9 Meters Biopharma executives and other stock owners filed with the SEC include: